- funding probability score
- total disclosed funding
- last round valuation estimate
- disclosed funding rounds
- latest round
- latest funding stage
- next round estimate
- development stage
- number of investors
- number of competitors
- monthly web visits
- twitter followers
Ole Maaløes Vej 3, Copenhagen, DK-2200, DNK
- Acesion Pharma is a Danish biotech company founded in 2011 by Morten Grunnet and Ulrik Sørensen together with the Danish venture funds Novo Seeds and SEED Capital.
Acesion Pharma is aiming for developing more efficacious and safer drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. AF is associated with impaired quality of life, increased rate of hospitalisation, and increased risk of stroke and death. It is recognised that existing drug therapies only have a limited effect and are often followed by risks of serious adverse events. Therefore, there is a high unmet need for better drugs for the medical treatment of AF.
The scientific foundation of Acesion Pharma is the novel concept of treating AF by inhibiting the so-called SK channels. These are ion channels present in the heart where they are relevant for regulating the cardiac rhythm. Blocking this ion channel with a selective drug molecule constitutes a novel and promising target for developing improved treatment of AF.
There is much more to this profile.
Log in or sign up for free to see the whole thing.
- Advanced search filters
- Full startup and investor profiles
- Follow startups and investors
- Custom follow-lists
- Startup benchmarking
- Network maps
- Market stats